New Product Development, Evaluation, With Optimization Diclofenac Transport For Gout

Abstract

Background: Gout is a common form of inflammatory arthritis. When this happens to one or more joints, it can cause inflammation, redness, and discomfort. Developing solid lipid nanoparticles (SLNs) containing diclofenac (DCE) was the primary objective of this research. Because of their reputation as the most effective lipid-based colloidal carriers, SLNs have become the standard approach for improving the oral bioavailability of drugs that have low water solubility.

Methodology: The microemulsion method was used to create diclofenac-loaded SLNs that were coated with chitosan (CS) for targeted drug delivery. Next, a battery of tests was run on them, including in vitro drug release in phosphate buffer, polydispersity index, and particle size.

Results: The formulation parameters of Diclofenac-SLN were optimized using the Box-Behnken design of response surface methodology. Particle size was 94.39 nm, PDI was 0.239, and entrapment efficacy was around 0.89 for the improved formulation. An 8.75 mV zeta potential is associated with diclofenac-SLN. TEM examination showed that Diclofenac-SLNs ranged in size from 100 nm and had a spherical form. Endothermic transitions occurred at 243°C in the DCE DSC curve. Over the course of a day, 85% of the medicine was released from the SLNs containing diclofenac, demonstrating a regulated release of the medication from the lipid matrix. When compared to pure drug solutions, optimized diclofenac-SLNs demonstrated sustained drug release for up to 24 hours in the drug release trials.

Conclusion: First, FTIR and physiological testing identified and purified the drug and polymer. The design strategy was followed to synthesize DCE and DCE-coupled SLNs using micro-emulsion technology. In-situ coating of SLNs with chitosan ligand improved oral bioavailability and maybe tailored drug distribution at the site of action. Lipid phase affinity for negatively charged Diclofenac was increased by cationic lipid stearic acid. The increased batch had a 300-nm diameter and 0.324 PDI, as proven by TEM and particle size analysis.